Reports
Sale
Global Critical Care Antiarrhythmic Drugs Market Size, Trends: By Drug Class: Beta Blockers, Calcium Chain Blockers, Sodium Channel Blockers, Potassium Channel Blockers, Others; By Diseases Type; By Route of Administration; By Treatment Channel; By End User; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Global Critical Care Antiarrhythmic Drugs Market Outlook
The global market value in 2023 was USD 1005.2 million, driven rising demand for advanced healthcare facilities across the globe. The critical care antiarrhythmic drugs market size is anticipated to grow at a CAGR of 5.6% during the forecast period of 2024-2032 to achieve a value of USD 1644.2 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America to be a Significant Regional Market for Critical Care Antiarrhythmic Drugs
North America represents a significant share of the critical care antiarrhythmic industry due to advancements in cutting-edge medical research and development (R&D) activities. The introduction of favourable reimbursement policies by governments and advanced health care infrastructure in the region is expected to surge the demand for critical care antiarrhythmic medicines and bolster the market growth in the forecast period. As several government-funded organisations, academic institutions, and private entities are intensely initiating clinical trials and drug development activities for effective treatment of complicated cardiac disorders, the market is poised to grow robustly in the coming years.
Europe is witnessing rapid growth owing to the increasing geriatric population with various health-related issues. The introduction of various favourable initiatives by governments to bolster the accessibility of healthcare is propelling the market growth. Further, the rising awareness regarding atrial fibrillation and associated heart conditions is anticipated to propel the regional market growth, which is estimated to significantly contribute to the growth of the overall industry.
Critical Care Antiarrhythmic Drugs: Market Segmentation
Critical care antiarrhythmic drugs refer to medications that are used in the treatment of arrhythmias during serious cardiovascular issues. They follow up on the heart's electrical conduction system trying to keep up the sinus beat. Calcium channel blockers, anti-adrenergic agents, antiarrhythmic agents, diuretic agents, and angiotensin-converting enzyme (ACE) inhibitors are some of the medications used to treat cardiac problems. Antiarrhythmic medications work by inhibiting aberrant cardiac rhythms caused by atrial flutter, atrial and ventricular fibrillation, and other irregular electrical activity of the heart.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By drug class, the market is divided into:
- Bovine
- Human
- Recombinant
- Others
Based on end-use, the market includes:
- Hospitals
- Diagnostics
- Others
The EMR report looks into the regional markets of critical care antiarrhythmic drugs like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Increasing Regulatory Approvals of Novel Drug Formulations Boosting the Market Growth of Critical Care Antiarrhythmic Drugs
The growth of the critical care antiarrhythmic drugs industry can be attributed to the increasing approvals and active support for novel medication formulations for antiarrhythmic treatment by regulatory agencies. This, in turn, is encouraging major companies to innovate and bolster production, allowing them to meet the growing demand for effective cardiac treatments, hence driving the market growth. Moreover, the increasing prevalence of cardiovascular diseases in both developed and developing countries is expected to fuel the antiarrhythmic drugs industry in the forecast period. With the growing focus on heart health, the demand for critical care antiarrhythmic drugs is increasing, hence driving the market growth. The surging research and development (R&D) activities in drug discovery is anticipated to provide further impetus to the market growth in the coming years.
Key Industry Players in the Global Critical Care Antiarrhythmic Drugs Market
The report gives a detailed analysis of the following key players in the global critical care antiarrhythmic drugs market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Pfizer
- GlaxoSmithKline plc
- Sanofi
- Mylan N.V.
- Upsher-Smith Laboratories LLC
- Novartis AG
- Mayne Pharma
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Diseases Type |
|
| Breakup by Route of Administration |
|
| Breakup by Treatment Channel |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Arrhythmias Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Arrhythmias Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Arrhythmia Epidemiology (2016-2031)
5.3 Europe Arrhythmia Epidemiology (2016-2031)
5.4 Asia-Pacific Arrhythmia Epidemiology (2016-2031)
5.5 Latin America Arrhythmia Epidemiology (2016-2031)
5.6 Middle East & Africa Arrhythmia Epidemiology (2016-2031)
6 Global Critical Care Antiarrhythmic Drugs Market Overview
6.1 Global Critical Care Antiarrhythmic Drugs Market Historical Value (2017-2023)
6.2 Global Critical Care Antiarrhythmic Drugs Market Forecast Value (2024-2032)
7 Global Critical Care Antiarrhythmic Drugs Market Landscape
7.1 Critical Care Antiarrhythmic Drugs: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Critical Care Antiarrhythmic Drugs: Product Landscape
7.2.1 Analysis by Drug Class
7.2.2 Analysis by Disease Type
7.2.3 Analysis by Route of Administration
8 Critical Care Antiarrhythmic Drugs Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Critical Care Antiarrhythmic Drugs Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Critical Care Antiarrhythmic Drugs Market Segmentation
11.1 Global Critical Care Antiarrhythmic Drugs Market by Drug Class
11.1.1 Market Overview
11.1.2 Beta Blockers
11.1.3 Calcium Chain Blockers
11.1.4 Sodium Channel Blockers
11.1.5 Potassium Channel Blockers
11.1.6 Others
11.2 Global Critical Care Antiarrhythmic Drugs Market by Diseases Type
11.2.1 Market Overview
11.2.2 Supraventricular Arrhythmias
11.2.3 Ventricular Arrhythmias
11.2.4 Others
11.3 Global Critical Care Antiarrhythmic Drugs Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.2.1 Tablets
11.3.2.2 Capsules
11.3.3 Parentals
11.3.3.1 Intravascular
11.3.3.2 Intramuscular
11.3.4 Others
11.4 Global Critical Care Antiarrhythmic Drugs Market by Treatment Channel
11.4.1 Market Overview
11.4.2 Public
11.4.3 Private
11.5 Global Critical Care Antiarrhythmic Drugs Market by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Specialty Clinics
11.5.4 Homecare Settings
11.5.5 Others
11.6 Global Critical Care Antiarrhythmic Drugs Market by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospital Pharmacy
11.6.3 Retail Pharmacy
11.6.4 Online Pharmacy
11.6.5 Others
11.7 Global Critical Care Antiarrhythmic Drugs Market by Region
11.7.1 Market Overview
11.7.2 North America
11.7.3 Europe
11.7.4 Asia Pacific
11.7.5 Latin America
11.7.6 Middle East and Africa
12 North America Critical Care Antiarrhythmic Drugs Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Critical Care Antiarrhythmic Drugs Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Critical Care Antiarrhythmic Drugs Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Critical Care Antiarrhythmic Drugs Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Critical Care Antiarrhythmic Drugs Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 F. Hoffmann-La Roche Ltd.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Fresenius Kabi AG
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Bayer AG
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Sun Pharmaceutical Industries Ltd.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Novartis AG
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Mylan N.V.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Teva Pharmaceutical Industries Ltd.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Pfizer Inc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Lupin
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 GSK Plc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Glenmark Pharmaceuticals Inc.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Amneal Pharmaceuticals
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
24 Critical Care Antiarrhythmic Drugs Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
In 2023, the global market for Critical Care Antiarrhythmic Drugs reached a value of USD 1005.2 million.
The market is anticipated to grow at a CAGR of 5.6% during the forecast period of 2024-2032 to reach a value of USD 1644.2 million by 2032.
The market is being aided by the expansion of health care infrastructure, the increasing geriatric population, and the surging clinical trials and drug development activities for effective treatment of complicated cardiac disorders.
The increasing approval of novel drugs, the rising prevalence of cardiovascular diseases, and the surging research and development (R&D) activities in drug discovery are estimated to propel the growth of the market.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The major drug classes of critical care antiarrhythmic drugs are bovine, human, and recombinant, among others.
The significant disease types of antiarrhythmic drugs in the market are hospitals and diagnostics, among others.
The major players in the industry are Pfizer, GlaxoSmithKline plc, Sanofi, Mylan N.V., Upsher-Smith Laboratories LLC, Novartis AG, and Mayne Pharma, among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5999
$2999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 7999
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9999
$5999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER